NEW YORK (GenomeWeb News) – EMD Millipore today announced a clinical research, licensing, and joint development deal with Japan's Sysmex aimed at creating a flow cytometry platform for blood disorders.

The companies will use EMD Millipore's flow cytometry technology as a platform to accelerate the development of new diagnostic tools. If successful, they will then develop the platform for commercialization in the hematology space, EMD Millipore, division of Germany's Merck KGaA, said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.